Filing Flows › Crispr Therapeutics AG (CRSP) › Q1 2025
Crispr Therapeutics AG (CRSP) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Crispr Therapeutics AG (CRSP) reported revenue of $865K for the first quarter 2025 (Q1 2025), +72% from a year earlier and -98% from the quarter before.
Crispr Therapeutics AG, Q1 2025: revenue $865K (+72% year over year), net loss $136M, operating cash flow −$53.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $865K | -98% | +72% |
| Operating profit | −$148M | — | — |
| Net earnings | −$136M | — | — |
| Operating cash flow | −$53.9M | — | — |
What changed
Revenue was $865K in Q1 2025, up 72% year over year and down 98% from the previous quarter.
Operating costs exceeded revenue by $148.4M, an operating margin of -17158.8%. Total costs grew 6% against revenue growth of 72%. The fastest-growing cost line was Other operating costs (+22%). The quarter ended with a net loss of $136.0M, wider than the previous quarter's $37.3M loss.
Operating cash flow was −$53.9M. Non-cash charges added back $4.7M of depreciation and amortization and $20.2M of share-based compensation. Working capital and other items added $57.1M. Capital expenditures of $206K exceeded it, leaving free cash flow of −$54.2M.
Questions
What was Crispr Therapeutics AG's revenue in the first quarter 2025?
Crispr Therapeutics AG (CRSP) reported revenue of $865K for the first quarter 2025 (Q1 2025), +72% from a year earlier and -98% from the quarter before.